

# FAX TRANSMISSION

**DATE:** April 19, 2005

**PTO IDENTIFIER:** Application Number 10/506592

Patent Number

**Inventor:** Andrew David Morley

**MESSAGE TO:** Office of Initial Patent Examination

**FAX NUMBER:** (703) 746-9195

**FROM:** ROPES & GRAY LLP

David P. Halstead, Ph.D.

**PHONE:** (617) 951-7615

**Attorney Dkt. #:** ASZD-P01-659

**PAGES (Including Cover Sheet):** 4

**CONTENTS:** Request for Corrected Filing Receipt (2 pages)

Copy of Incorrect Filing Receipt with Changes Noted Thereon (2 pages)

This Facsimile Cover Sheet (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7615 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**ROPES & GRAY LLP**

One International Place, Boston, Massachusetts 02110-2624

Telephone: (617) 951-7000 Facsimile: (617) 951-7050

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 746-9195, on the date shown below.

Dated: April 18, 2005Signature: 

(Mary Jane Morley)

Docket No.: ASZD-P01-659  
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Andrew David Morley

Application No.: 10/506592

Confirmation No.: 2926

Filed: September 3, 2004

Art Unit: 1615

For: INDOLE-AMIDE DERIVATIVES AND THEIR  
USE AS GLYCOGEN PHOSPHORYLASE  
INHIBITORS

Examiner: Not Yet Assigned

**REQUEST FOR CORRECTED FILING RECEIPT**

Filing Receipt Corrections  
Office of Initial Patent Examination  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has an error in the title:

Please change the title from "Chemical compounds" to --Indole-amide derivatives and their use as glycogen phosphorylase inhibitors--.


The correct title is noted on the Application Data Sheet, the Combined Declaration and Power of Attorney, and on the first page of the Substitute Specification that were filed with the application on September 3, 2004.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. ASZD-P01-659 from which the undersigned is authorized to draw.

Dated: April 19, 2005

Respectfully submitted,

By   
David P. Halstead, Ph.D.  
Registration No.: 44,735  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

| APPL NO.   | FILING OR 371<br>(C) DATE | ART UNIT | FIL FEE RECD | ATTY.DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|--------------|----------------|----------|----------|----------|
| 10/506,592 | 09/03/2004                | 1615     | 920          | ASZD-P01-659   |          | 13       | 1        |

## CONFIRMATION NO. 2926

28120  
 FISH & NEAVE IP GROUP  
 ROPES & GRAY LLP  
 ONE INTERNATIONAL PLACE  
 BOSTON, MA 02110-2624

## FILING RECEIPT



\*OC00000015566286\*

Date Mailed: 03/30/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Andrew David Morley, Cheshire, UNITED KINGDOM;

Power of Attorney: The patent practitioners associated with Customer Number 28120.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/00936 03/04/2003

## Foreign Applications

UNITED KINGDOM 0205168.2 03/06/2002

Projected Publication Date: 06/30/2005

Non-Publication Request: No

Early Publication Request: No

Title

Chemical compounds

Ropes & Gray  
 Symbol #: ASZD-P01-659

Ropes &amp; Gray

Action Due: Review fil APR 12 2005  
 Deadline(s): 30 Apr 2005

APR 12 2005

Intellectual Property Dept.

INDOLE-AMIDE DERIVATIVES  
 AND THEIR USE AS GLYCOGEN PHOSPHORYLASE  
 INHIBITORS

**Preliminary Class**  
514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (l)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).